awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q36805474-2CD7DD4D-171F-4072-8771-0B0BF7D880E7
Q36805474-2CD7DD4D-171F-4072-8771-0B0BF7D880E7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36805474-2CD7DD4D-171F-4072-8771-0B0BF7D880E7
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group
P2860
Q36805474-2CD7DD4D-171F-4072-8771-0B0BF7D880E7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36805474-2CD7DD4D-171F-4072-8771-0B0BF7D880E7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8cad2c05cdb54071c1bb9a81144bfaee6cab4d06
P2860
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.